Company news
Hemogenyx Pharmaceuticals Plc (LSE:HEMO) news
Hemogenyx Pharmaceuticals Plc news releases on 6ix. Latest, Jul 1, 2022: Change of Registered Office
Press releases — page 3
Change of Registered Office
July 1, 2022
Investor Webinar
June 27, 2022
Director/PDMR Shareholding
May 30, 2022
Immuno-Oncology Summit Europe Presentation
May 16, 2022
Final Results for the Year Ended 31 December 2021
April 29, 2022
CBR Update
March 16, 2022
HEMO-CAR-T pre-IND Meeting Request
February 16, 2022
Hemogenyx Pharmaceuticals Partnership with Selexis
January 12, 2022
H.C. Wainwright Bioconnect Conference
January 5, 2022
Hemo-CAR-T partnership with WuXi ATU
December 20, 2021
Convertible Loans Repayment
November 24, 2021
Lease of New York Mink Building Custom Laboratory
October 18, 2021
CDX Licence Agreement
October 13, 2021
U.S. Approval of Monoclonal Antibody Patent
September 2, 2021
Appointment of Business Advisor & Board Observer
July 26, 2021
Corporate Presentation
July 2, 2021
Changes to 2021 AGM Arrangements
June 15, 2021
U.S. Approval and Issuance of CDX Antibody Patent
June 2, 2021
Termination of Mint Facility; Admission of Shares
May 26, 2021
Loan Notes Sale & Conversion; Facility Terminated
May 18, 2021
Publication of Supplementary Prospectus
May 12, 2021
Conversion of Convertible Loan Notes
May 5, 2021
CDX Option Update
April 14, 2021
CDX Antibody Update
April 1, 2021
Allotment of Shares
March 29, 2021
H.C. Wainwright Investment Conference
March 8, 2021
HEMO-CAR-T Update
March 3, 2021
Draw Down Under Financing Facility Agreement
February 3, 2021
Publication of Prospectus
January 29, 2021
Update on CDX Antibody Development
January 13, 2021
Result of General Meeting
January 6, 2021
CAR-T Master Translational Agreement with Penn
January 5, 2021
Change to Date of General Meeting
December 8, 2020
Posting of Circular
December 2, 2020
Financing Facility of up to £60 Million
November 18, 2020
CDX Development Agreement Further Extension
October 27, 2020
Presentation at the American Society of Hematology
October 19, 2020
SAFE-HEMO-CAR-T Effective against AML in vitro
October 6, 2020
Interim Results for the period ended 30 June 2020
September 30, 2020
Further re. Grant of Options
September 22, 2020
Grant of Options
August 21, 2020
Presentations at Cancer Immunotherapy Symposia
August 14, 2020
CAR-T Agreement with University of Pennsylvania
August 11, 2020
Broker's Research Note
July 31, 2020
Further re Development Agreement
July 13, 2020
US Subsidiary Change of Name
July 10, 2020
New Corporate Video and Investor Webinar
July 6, 2020
Development Agmnt - Autoimmune Disease Treatments
June 26, 2020
Hemogenyx Chairman Receives Tang Prize
June 24, 2020
COVID-19 Project Update
June 15, 2020